Bosnia and Herzegovina vs South Africa: Percentage of bloodstream infection due to Escherichia coli resistant
Bosnia and Herzegovina
26.8%
in 2022
South Africa
30.0%
in 2022
Bosnia and Herzegovina rank
28th
South Africa rank
27th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Bosnia and Herzegovina
- South Africa
How they compare
South Africa currently reports 30.0% against 26.8% in Bosnia and Herzegovina, a difference of 3.2%.
That makes South Africa's figure about 1.1 times Bosnia and Herzegovina's.
The two have swapped places 2 times across 5 shared years of data; in 2018 it was South Africa ahead.
Bosnia and Herzegovina ranks 28th and South Africa ranks 27th of 50 countries.
South Africa has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.3% | 30.6% | 10.3% | South Africa |
| 2020s | 26.4% | 28.6% | 2.3% | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Bosnia and Herzegovina or South Africa?
- South Africa, at 30.0% against 26.8% in Bosnia and Herzegovina as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Bosnia and Herzegovina and South Africa?
- 3.2%, with South Africa ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and South Africa?
- 5 years are reported by both, from 2018 to 2022.
- How do Bosnia and Herzegovina and South Africa rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Bosnia and Herzegovina ranks 28th and South Africa ranks 27th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.